Modification of Parkinsonism--chronic treatment with L-dopa

N Engl J Med. 1969 Feb 13;280(7):337-45. doi: 10.1056/NEJM196902132800701.
No abstract available

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Agranulocytosis / chemically induced
  • Aromatic Amino Acid Decarboxylase Inhibitors
  • Blood Urea Nitrogen
  • Blood-Brain Barrier / drug effects
  • Chronic Disease
  • Dihydroxyphenylalanine / administration & dosage*
  • Dihydroxyphenylalanine / adverse effects
  • Dihydroxyphenylalanine / metabolism
  • Dihydroxyphenylalanine / toxicity
  • Dihydroxyphenylalanine / urine
  • Dopamine / urine
  • Feeding and Eating Disorders / chemically induced
  • Female
  • Humans
  • Huntington Disease / drug therapy
  • Male
  • Manganese / blood
  • Mental Processes / drug effects
  • Methyldopa / administration & dosage
  • Middle Aged
  • Movement Disorders / chemically induced
  • Nausea / chemically induced
  • Neurologic Manifestations
  • Parkinson Disease / drug therapy*
  • Phenylacetates / urine
  • Placebos
  • Thyroid Function Tests
  • Tyrosine / metabolism
  • Vomiting / chemically induced

Substances

  • Aromatic Amino Acid Decarboxylase Inhibitors
  • Phenylacetates
  • Placebos
  • Tyrosine
  • Manganese
  • Methyldopa
  • Dihydroxyphenylalanine
  • Dopamine